Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast Emrelis Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    Emrelis (telisotuzumab vedotin-tllv) Coverage Criteria

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and Part B medical coverage for physician-administered intravenous Emrelis in adults with specified locally advanced or metastatic non-squamous non-small cell lung cancer. It establishes the covered indication, clinical approval criteria, dosing, administration setting, monitoring, and authorization duration.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyEmrelis (telisotuzumab vedotin-tllv) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 13, 2025
    Last ReviewNov 13, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization for physician-administered Emrelis IV infusion with documentation that all approval criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1.9 mg/kgDose every two weeks
    190 mgMaximum dose
    ≥50%High c-Met expression required
    6 monthsInitial coverage

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 monthsReauthorization
    ≥18Minimum age

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following criteria are met:

    ALL of the following

    • Patient is an adult age ≥ 18 years.
    • Diagnosis of non-squamous non-small cell lung cancer (NSCLC).
    • Disease is recurrent, locally advanced, or metastatic.
    • Disease has ALL of the following characteristics

      • Non-squamous histology.
      • High c-Met protein overexpression, defined as present in ≥ 50% of tumor cells.
      • Strong (3+) immunohistochemistry staining (IHC 3+).
      • EGFR wild-type.
    • Patient has received prior systemic therapy for NSCLC.
    • Emrelis is prescribed by or in consultation with an oncologist.
    • Request is for single-agent therapy.
    • ONE of the following dosing requirements is met

      • Dose does not exceed 1.9 mg/kg by IV infusion every two weeks, with a maximum dose of 190 mg.
      • Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, and the prescriber submits supporting evidence.

    Continuation Therapy

    Continuation therapy may be authorized when ALL of the following are met:

    ALL of the following

    • Patient continues treatment for recurrent, locally advanced, or metastatic non-squamous NSCLC with Emrelis.
    • Patient is deriving clinical benefit and treatment remains clinically appropriate; therapy has not been discontinued because of disease progression or unacceptable toxicity.
    • Dose remains consistent with FDA-approved labeling or accepted standards of medical practice, generally not exceeding 1.9 mg/kg by IV infusion every two weeks, with a maximum dose of 190 mg.
    • Reauthorization is requested within the applicable coverage period; continuation coverage may be authorized for up to 12 months.

    Emrelis must be administered as a physician-administered IV infusion in an office or hospital outpatient department (HOPD). Self-administration is not covered.

    Avoid use of Emrelis in patients with moderate to severe hepatic impairment, defined as total bilirubin > 1.5 times the upper limit of normal (ULN) and any AST, because increased MMAE exposure may increase adverse reactions.

    Codes and Dosing

    HCPCS CodeHCPCSCovered
    J9326Injection, telisotuzumab vedotin-tllv, 1 mg
    NDC CodesNDCCovered
    0074-1044-01Emrelis 20 mg single-dose vial, 10-digit NDC
    0074-1055-01Emrelis 100 mg single-dose vial, 10-digit NDC
    00074-1044-01Emrelis 20 mg single-dose vial, 11-digit NDC
    00074-1055-01Emrelis 100 mg single-dose vial, 11-digit NDC
    Emrelis dose
    Dose1.9 mg/kg by IV infusion
    FrequencyEvery two weeks
    Maximum dose190 mg for patients weighing at least 100 kg
    High c-Met expression
    Expression thresholdAt least 50% of tumor cells
    Staining intensityStrong 3+ immunohistochemistry staining
    Testing methodDetermined by an FDA-approved test

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Emrelis (telisotuzumab vedotin-tllv) administered by physician-directed IV infusion. Submit the request with documentation showing that the applicable approval criteria are met.

    • Administration must be in an office or hospital outpatient department (HOPD).
    • Requests are subject to the diagnosis, disease-status, biomarker, prior-treatment, dosing, and other requirements below.
    Documentation Required

    Prior Systemic Therapy Must Be Documented

    Document that the patient has received prior systemic therapy for advanced or metastatic non-small cell lung cancer (NSCLC). Examples include the following regimens:

    • Bevacizumab + carboplatin + paclitaxel
    • Bevacizumab + carboplatin + pemetrexed

    Drug and Indication Background

    Emrelis (telisotuzumab vedotin-tllv) is a c-Met-directed antibody and microtubule inhibitor conjugate indicated for adults with recurrent, locally advanced, or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression, defined as expression in at least 50% of tumor cells with strong (3+) immunohistochemistry staining, after prior systemic therapy.

    Policy Definitions

    High c-Met protein overexpression
    BiomarkerHigh c-Met protein overexpression
    Tumor-cell thresholdPresent in at least 50% of tumor cells
    Staining requirementStrong 3+ immunohistochemistry staining
    Moderate-to-severe hepatic impairment
    Total bilirubinGreater than 1.5 times the upper limit of normal
    ASTAny AST elevation
    Clinical classificationModerate-to-severe hepatic impairment

    Initial Therapy Approval

    Initial Therapy Approval

    Initial coverage requires that all approval criteria be met:

    Initial Emrelis therapy

    • The patient is an adult aged 18 years or older with recurrent, locally advanced, or metastatic non-squamous NSCLC.Age ≥18 years
    • The tumor has high c-Met protein overexpression in at least 50% of tumor cells with strong (3+) immunohistochemistry staining.c-Met ≥50% of tumor cells; strong (3+) IHC staining
    • The disease is EGFR wild-type.
    • The patient has received prior systemic therapy for NSCLC.

    Continuation of Emrelis

    Prior Systemic Therapy

    StepRequirementExamples of prior systemic therapy
    1The patient must have received prior systemic therapy for non-squamous NSCLC before starting Emrelis.Examples include bevacizumab plus carboplatin and paclitaxel or pemetrexed; Imjudo plus Imfinzi with carboplatin and albumin-bound paclitaxel, pemetrexed, or cisplatin/pemetrexed; Keytruda plus carboplatin or cisplatin and pemetrexed; Libtayo plus carboplatin or cisplatin and pemetrexed; Opdivo plus Yervoy, with or without pemetrexed and carboplatin or cisplatin; Tecentriq plus carboplatin and albumin-bound paclitaxel; and Tecentriq plus carboplatin, paclitaxel, and bevacizumab.

    Dose and Quantity Limits

    Emrelis quantity limits
    DrugEmrelis
    Quantity limit1.9 mg/kg, maximum 190 mg
    Administration intervalPer IV infusion every two weeks

    Administration Setting

    Billing Rule

    Office administration

    Administer Emrelis as a physician-administered IV infusion in the office. The drug cannot be self-administered.

    • Route: IV infusion
    • Administration: physician administered
    • Setting: office
    Billing Rule

    Hospital outpatient administration

    Hospital outpatient department administration is permitted when Emrelis is provided as a physician-administered IV infusion.

    • Setting: hospital outpatient department
    • Route: physician-administered IV infusion
    Policy Summary
    PayerGold Coast Health Plan
    PolicyEmrelis (telisotuzumab vedotin-tllv) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 13, 2025
    Last ReviewNov 13, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization for physician-administered Emrelis IV infusion with documentation that all approval criteria are met.
    SourceLink
    On This Page
    Coverage CriteriaCodes and DosingAuthorization and Documentation RequirementsDrug and Indication BackgroundPolicy DefinitionsInitial Therapy ApprovalContinuation of EmrelisPrior Systemic TherapyDose and Quantity LimitsAdministration Setting
    Hepatic impairment avoidance threshold
    Total bilirubin thresholdGreater than 1.5 times the upper limit of normal
    AST criterionAny AST elevation
    Policy actionAvoid Emrelis use
  1. Imjudo + Imfinzi + carboplatin + albumin-bound paclitaxel
  2. Imjudo + Imfinzi + carboplatin + pemetrexed
  3. Imjudo + Imfinzi + cisplatin + pemetrexed
  4. Keytruda + carboplatin + pemetrexed
  5. Keytruda + cisplatin + pemetrexed
  6. Libtayo + carboplatin + pemetrexed
  7. Libtayo + cisplatin + pemetrexed
  8. Opdivo + Yervoy
  9. Opdivo + Yervoy + pemetrexed + carboplatin
  10. Opdivo + Yervoy + pemetrexed + cisplatin
  11. Tecentriq + carboplatin + albumin-bound paclitaxel
  12. Tecentriq + carboplatin + paclitaxel + bevacizumab
  13. Documentation Required

    Clinical Eligibility Documentation

    Submit clinical documentation confirming that the patient meets the disease and biomarker requirements for Emrelis.

    • Diagnosis of non-squamous NSCLC.
    • Recurrent, locally advanced, or metastatic disease.
    • High c-Met protein overexpression, defined as c-Met expression in at least 50% of tumor cells with strong (3+) immunohistochemistry staining (IHC 3+).
    • EGFR wild-type disease.
    • Patient is an adult age 18 years or older.
    • Emrelis is prescribed by, or in consultation with, an oncologist and requested as single-agent therapy.
    Documentation Required

    Off-Label Supporting Evidence Required

    For an off-label request, provide the requested dosing details and supporting evidence. Coverage may be considered when the dose is within the stated limit or when the relevant off-label use is supported by accepted evidence.

    • Dose must not exceed 1.9 mg/kg, with a maximum dose of 190 mg, every two weeks; or
    • Submit practice guidelines or peer-reviewed literature supporting the relevant off-label use.
    Note

    Safety Monitoring Required

    Monitor patients throughout treatment for clinically significant adverse reactions and document the monitoring plan. Emrelis dosing may be delayed, reduced, or permanently discontinued according to the severity of adverse reactions.

    • Peripheral neuropathy.
    • Interstitial lung disease (ILD) or pneumonitis.
    • Ocular surface disorders.
    • Infusion-related reactions (IRR).
    • Embryo-fetal toxicity: verify pregnancy status before treatment in females of reproductive potential and counsel on effective contraception during treatment and for two months after the last dose.
    • Monitor closely when coadministered with strong CYP3A inhibitors, which may increase unconjugated MMAE exposure and adverse reactions.
    Denial Risk

    Failure to Meet Approval Criteria

    Requests may be denied when the documentation does not establish all applicable approval requirements for Emrelis.

    • The diagnosis is not non-squamous NSCLC, or the disease is not recurrent, locally advanced, or metastatic.
    • High c-Met overexpression is not documented as at least 50% of tumor cells with strong (3+) IHC staining, or EGFR wild-type status is not established.
    • Prior systemic therapy for NSCLC, adult age, oncologist involvement, or single-agent use is not documented.
    • The requested dose exceeds 1.9 mg/kg or 190 mg every two weeks without qualifying supporting evidence.
    • The request lacks required prior authorization documentation or applicable practice-guideline or peer-reviewed literature support for off-label use.
    Denial Risk

    Avoid Use in Moderate-to-Severe Hepatic Impairment

    Avoid Emrelis in patients with moderate-to-severe hepatic impairment because increased MMAE exposure may increase adverse reactions.

    • Do not use when total bilirubin is greater than 1.5 times the upper limit of normal (ULN) with any AST.
    Billing Rule

    Physician-Administered IV Infusion Required

    Emrelis cannot be self-administered. It must be provided as a physician-administered IV infusion in an approved setting.

    • Administration is limited to an in-office or hospital outpatient department (HOPD) setting.
    • Self-administration or an unapproved site or route of administration does not meet the approval requirements.
  14. The drug is prescribed by or in consultation with an oncologist.
  15. The request is for single-agent therapy.
  16. ONE of the following dosing requirements

    • The dose does not exceed 1.9 mg/kg, up to a maximum of 190 mg, every two weeks.1.9 mg/kg; maximum 190 mg every two weeks
    • The requested off-label use is supported by practice guidelines or peer-reviewed literature, and the prescriber submits the supporting evidence.
  17. Administration is by physician-administered IV infusion in an office or hospital outpatient department; Emrelis cannot be self-administered.
  18. Emrelis is avoided in patients with moderate to severe hepatic impairment.Total bilirubin >1.5 times the upper limit of normal and any AST elevation